{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T07:06:26Z","timestamp":1776668786128,"version":"3.51.2"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"vor","delay-in-days":41,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CAMS Innovation Fund for Medical Sciences","award":["2024-I2M-C&T-B-017"],"award-info":[{"award-number":["2024-I2M-C&T-B-017"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15815-8","type":"journal-article","created":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:45:33Z","timestamp":1773153933000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study"],"prefix":"10.1186","volume":"26","author":[{"given":"Lili","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong","family":"Liang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Runfeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongli","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqi","family":"Qin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,3,10]]},"reference":[{"issue":"2","key":"15815_CR1","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, et al. Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma. N Engl J Med. 2022;387(2):132\u201347.","journal-title":"N Engl J Med"},{"issue":"2","key":"15815_CR2","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjh.15261","volume":"182","author":"EK O\u2019Donnell","year":"2018","unstructured":"O\u2019Donnell EK, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018;182(2):222\u201330.","journal-title":"Br J Haematol"},{"issue":"9","key":"15815_CR3","doi-asserted-by":"publisher","first-page":"1802","DOI":"10.1002\/ajh.27422","volume":"99","author":"SV Rajkumar","year":"2024","unstructured":"Rajkumar SV, Multiple myeloma. 2024 update on diagnosis, risk-stratification, and management. Am J Hematol. 2024;99(9):1802\u201324.","journal-title":"Am J Hematol"},{"issue":"4","key":"15815_CR4","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJMoa2312054","volume":"390","author":"P Sonneveld","year":"2024","unstructured":"Sonneveld P, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;390(4):301\u201313.","journal-title":"N Engl J Med"},{"issue":"26","key":"15815_CR5","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863\u20139.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15815_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1038\/leu.2013.247","volume":"28","author":"WJ Chng","year":"2014","unstructured":"Chng WJ, et al. IMWG consensus on risk stratification in multiple myeloma. Leukemia. 2014;28(2):269\u201377.","journal-title":"Leukemia"},{"issue":"24","key":"15815_CR7","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, et al. International Myeloma Society\/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma. J Clin Oncol. 2025;43(24):2739\u201351.","journal-title":"J Clin Oncol"},{"issue":"5","key":"15815_CR8","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41408-022-00679-5","volume":"12","author":"PJ Hagen","year":"2022","unstructured":"Hagen PJ, Zhang, Barton K. High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions. Blood Cancer J. 2022;12(5):83.","journal-title":"Blood Cancer J"},{"issue":"23","key":"15815_CR9","doi-asserted-by":"publisher","first-page":"3945","DOI":"10.1200\/JCO.22.02567","volume":"41","author":"MF Kaiser","year":"2023","unstructured":"Kaiser MF, et al. Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple Myeloma. J Clin Oncol. 2023;41(23):3945\u201355.","journal-title":"J Clin Oncol"},{"issue":"11","key":"15815_CR10","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1001\/jamaoncol.2020.4338","volume":"6","author":"S Giri","year":"2020","unstructured":"Giri S, et al. Evaluation of Daratumumab for the Treatment of Multiple Myeloma in Patients With High-risk Cytogenetic Factors: A Systematic Review and Meta-analysis. JAMA Oncol. 2020;6(11):1759\u201365.","journal-title":"JAMA Oncol"},{"issue":"25","key":"15815_CR11","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1200\/JCO.21.01935","volume":"40","author":"LJ Costa","year":"2022","unstructured":"Costa LJ, et al. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2022;40(25):2901\u201312.","journal-title":"J Clin Oncol"},{"issue":"4","key":"15815_CR12","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.mayocp.2013.01.019","volume":"88","author":"JR Mikhael","year":"2013","unstructured":"Mikhael JR, et al. Management of newly diagnosed symptomatic multiple myeloma: updated Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus guidelines 2013. Mayo Clin Proc. 2013;88(4):360\u201376.","journal-title":"Mayo Clin Proc"},{"issue":"8","key":"15815_CR13","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020;136(8):936\u201345.","journal-title":"Blood"},{"key":"15815_CR14","doi-asserted-by":"publisher","first-page":"1286029","DOI":"10.3389\/fonc.2024.1286029","volume":"14","author":"W Tang","year":"2024","unstructured":"Tang W, et al. Daratumumab-based immunotherapy vs. lenalidomide, bortezomib and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: a systemic review. Front Oncol. 2024;14:1286029.","journal-title":"Front Oncol"},{"issue":"17","key":"15815_CR15","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1056\/NEJMoa2400712","volume":"391","author":"T Facon","year":"2024","unstructured":"Facon T, et al. Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2024;391(17):1597\u2013609.","journal-title":"N Engl J Med"},{"issue":"10","key":"15815_CR16","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1016\/S2352-3026(23)00217-X","volume":"10","author":"PM Voorhees","year":"2023","unstructured":"Voorhees PM, et al. Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial. Lancet Haematol. 2023;10(10):e825\u201337.","journal-title":"Lancet Haematol"},{"issue":"8","key":"15815_CR17","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1038\/bcj.2014.55","volume":"4","author":"J Lu","year":"2014","unstructured":"Lu J, et al. Clinical features and treatment outcome in newly diagnosed Chinese patients with multiple myeloma: results of a multicenter analysis. Blood Cancer J. 2014;4(8):e239.","journal-title":"Blood Cancer J"},{"issue":"5","key":"15815_CR18","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1007\/s00277-021-04475-2","volume":"100","author":"Y Jin","year":"2021","unstructured":"Jin Y, et al. The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma. Ann Hematol. 2021;100(5):1251\u201360.","journal-title":"Ann Hematol"},{"issue":"4","key":"15815_CR19","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1038\/s41591-024-03485-7","volume":"31","author":"SZ Usmani","year":"2025","unstructured":"Usmani SZ, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial. Nat Med. 2025;31(4):1195\u2013202.","journal-title":"Nat Med"},{"issue":"16","key":"15815_CR20","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1097\/CM9.0000000000001678","volume":"134","author":"GZ Yang","year":"2021","unstructured":"Yang GZ, et al. Autologous peripheral blood stem cell transplantation as front-line therapy for myeloma with double-hit and triple-hit in a real-world study. Chin Med J (Engl). 2021;134(16):1991\u20133.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"15815_CR21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1200\/JCO.23.01696","volume":"42","author":"LB Leypoldt","year":"2024","unstructured":"Leypoldt LB, et al. Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma. J Clin Oncol. 2024;42(1):26\u201337.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15815_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-024-01030-w","volume":"14","author":"NS Callander","year":"2024","unstructured":"Callander NS, et al. Daratumumab-based quadruplet therapy for transplant-eligible newly diagnosed multiple myeloma with high cytogenetic risk. Blood Cancer J. 2024;14(1):69.","journal-title":"Blood Cancer J"},{"issue":"1","key":"15815_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/S1470-2045(22)00693-3","volume":"24","author":"R Mina","year":"2023","unstructured":"Mina R, et al. Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. Lancet Oncol. 2023;24(1):64\u201376.","journal-title":"Lancet Oncol"},{"issue":"20","key":"15815_CR24","doi-asserted-by":"publisher","first-page":"2029","DOI":"10.1182\/blood.2023023597","volume":"143","author":"C Touzeau","year":"2024","unstructured":"Touzeau C, et al. Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 2024;143(20):2029\u201336.","journal-title":"Blood"},{"issue":"1","key":"15815_CR25","doi-asserted-by":"publisher","first-page":"2161222","DOI":"10.1080\/16078454.2022.2161222","volume":"28","author":"C Geng","year":"2023","unstructured":"Geng C, et al. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era. Hematology. 2023;28(1):2161222.","journal-title":"Hematology"},{"issue":"14","key":"15815_CR26","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1056\/NEJMoa1611750","volume":"376","author":"M Attal","year":"2017","unstructured":"Attal M, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017;376(14):1311\u201320.","journal-title":"N Engl J Med"},{"issue":"11","key":"15815_CR27","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","volume":"22","author":"T Facon","year":"2021","unstructured":"Facon T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582\u201396.","journal-title":"Lancet Oncol"},{"issue":"6","key":"15815_CR28","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41571-025-01017-x","volume":"22","author":"B Paiva","year":"2025","unstructured":"Paiva B, et al. Opportunities and challenges for MRD assessment in the clinical management of multiple myeloma. Nat Rev Clin Oncol. 2025;22(6):424\u201338.","journal-title":"Nat Rev Clin Oncol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15815-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15815-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15815-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T06:16:38Z","timestamp":1776665798000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15815-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,10]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15815"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15815-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,10]]},"assertion":[{"value":"30 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Medical Ethics Committeeat Peking Union Medical College Hospital(approval number: 1-23PJ504) and conducted in accordance with the principles outlined in the Declaration of Helsinki. All patients provided written informed consent prior to study participation.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have approved the manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"497"}}